LSSIElgin

Lutheran Social Services of Illinois Resource Guide

Starting Young

Insight into adolescent addiction comes as new guidelines urge early prevention

Emotional Eating

Still Effective After All These Years After 80 years, AA still works No Woman No Cry The woman who doesn’t feel

The Opiate EPIDEMIC

Lutheran Social Services of Illinois CONTACT US TODAY! 847.635.4600 issi.org

675 Varsity Dr. Elgin, IL 60120

EMDR Therapy What is EMDR therapy and how does it work? EMDR is the acronym for Eye Movement Desensitization and

Reprocessing. It was created by Francine Shapiro in 1987 and is now recommended by the Department of Veteran’s Affairs, the American Psychiatric Association, and most recently World Health Organization as very effective and efficient at helping people process traumatic events. Here is a list of typical problems that people seek EMDR therapy for: • Childhood or Adult Abuse • Extreme Illness or Grief • Post Traumatic Stress Disorder • Anger • Car Accidents • Sexual Traumas • Assault Trauma • Emotional Pain, Emotional Outbursts • Relationship problems • Phobias (including social ones) • Low Self-Confidence or Self Image • Sadness, Depression & Anxiety • Sleep Problems

EMDR is the acronym for Eye Movement Desensitization and Reprocessing.

• Intrusive thoughts, flashbacks • Being “on guard” all the time • Being Jumpy or Irritable • Substance abuse • Numbed Emotions

8

Fortunately not everyone has experienced extreme neglect or trauma, however, we have all experienced being humiliated, feeling rejected, unimportant, having our emotions hurt one way or another and all of these incidences are what we call “little t-trauma” that “help” reinforce the negative beliefs we have created in our minds usually from childhood experiences.These negative beliefs (negative cognitions as we call them in EMDR) lead to automatic responses every time we get “triggered” and we react in ways that is not authentic to who we are now or how we WANT to respond.

These negative beliefs (negative cognitions as we call them in EMDR) lead to automatic responses every time we get “triggered” and we react in ways that is not authentic to who we are now or how we WANT to respond.

When we do EMDR we use bilateral stimulation, which could be eye- movements from side to side, wearing headphones that produce a tone going from one ear to the other, or holding small paddles in your hands that vibrate slightly and produce bilateral stimulation kinetically.There is a specific 8 step protocol that the EMDR trained therapist guides you through which “untangles” the memory and finally allows your brain to store it properly so that it no longer creates those knee-jerk reactions from you that do not serve you well. If you are feeling “stuck” and unable to move beyond the things that are holding you back, call me at (386) 492-0778 and let us discuss how we can get you where you want to be.

9

Lutheran Social Services of Illinois CONTACT US TODAY! 847.635.4600 issi.org

675 Varsity Dr. Elgin, IL 60120

Giving addicts a “reset ” Developers working on first digital therapy app for addiction One reason the opioid addiction epidemic has taken hold in many rural areas is that many Americans with substance use disorder live long distances from the nearest treatment providers. But a new tool may provide hope.The U.S Food and Drug Administration (FDA) is currently reviewing a new tool that may help remedy that geographical problem: the first prescription digital therapy designed to treat SUD. Boston and San Francisco-based Pear Therapeutics developed reSET, a mobile app used as a treatment tool concurrently with outpatient therapy centered on SUDs.The project has demonstrated better abstinence and treatment retention when applied alongside face-to-face therapy focused on SUD-related treatments for alcohol, marijuana, cocaine and stimulants.The therapy also includes a web-based program for healthcare providers. An app to help opiate addicts Pear is also developing reSET-0, an app specifically designed to help opiate addicts. Both apps consist of a patient-facing smartphone application and a clinician-facing web interface. The company raised $20 million last year with the aid of various venture companies including Arboretum Ventures, an Ann Arbor, Mich.-based venture capital firm. “(reSET) will give patients and clinicians a new tool to improve therapy specifically in an area right now that is a true health epidemic in the U.S,” Dr.Thomas Shehab, managing director at Arboretum Ventures, told DrugAddictionNow.com. “It’s an extremely novel approach to central nervous system and behavioral health diseases that we didn’t see anyone else addressing in that way.”

Pear submitted reSET for review by the FDA during the first half of 2016 and says it is expected to be approved this year. Dr. Shehab said his firm is “particularly intrigued by their approach because it’s a combination of a very well-studied digital therapy being used in conjunction with other therapies.” He says, “We thought the unique makeup of the Pear team and their unique approach to digital therapies really made us feel it had the highest likelihood of success in really helping address these issues.”

16

According to data provided by Pear Therapeutics, 507 people with SUD from 10 treatment centers nationally received either face-to-face therapy or reduced volume of face-to-face therapy with reSET.They were given 12 weeks of outpatient therapy with or without using the app; if without, a portion of the digital therapy was replaced with face-to-face therapy. Abstinence was calculated two times weekly through a breathalyzer, urine samples and self-reports. Of the participants dependent on alcohol, marijuana, cocaine and stimulants, 58.1 percent of them receiving treatment with reSET were abstinent during weeks nine through 12, versus 29.8 percent of participants receiving only face-to-face therapy. Of the participants who started the study with a positive drug test, 26.7 percent of them who received reSET were abstinent during weeks nine through 12 of the study; only 3.2 percent of those that received traditional face-to-face therapy reported abstinence during the same time period. Participants using reSET presented statistically significant advancement in retention rates compared to those not using the app. After 12 weeks, 59 percent of participants that received face-to-face therapy retained sobriety in comparison to the 67 percent of those that used reSET.The reSET-O app has shown promising results in

three independent and randomized clinical trials, the company says. A study of 465 participants that completed outpatient methadone or buprenorphine treatment for opioid addiction was conducted, in which the participants were given standardized face-to-face therapy or shortened standardized treatment with reSET-O.Their abstinence was determined by self-reporting and urine tests. The developers plan to submit reSET-O to the FDA for approval, pending approval of reSET. “With all that’s going on, this is a very exciting company that we’re very enthusiastic about because it benefits a group of patients in great need,” Dr. Shehab said. “We think that reSET has a lot of potential.”

Maker receives NIDA grant In July, Pear announced it

has received a Small Business Innovation Research (SBIR) Fast-Track award funded by the National Institute on Drug Abuse (NIDA). PEAR will collaborate with CleanSlate Research and Education Foundation and Columbia University Medical Center Department of Psychiatry’s Division on Substance Use Disorders on the project. The grant will support the application of “enhanced engagement and gamification mechanisms” to reSET and reSET-O, the company says.

“It benefits a group of patients in great need.” - Dr.Thomas Shehab, Arboretum Ventures

17

Lutheran Social Services of Illinois CONTACT US TODAY! 847.635.4600 issi.org

675 Varsity Dr. Elgin, IL 60120

STUDY METHODOLOGY Studying mice genetically modified to be without the Nav1.7 channel, Wood found that such mice had bodies that dis- played a large increase in certain genes responsible for creating opioid peptides. Opioid peptides occur naturally in the body as the body’s painkiller and have a similar effect as opioids. In making more of the opioid pep- tides, the mice were blocking any feelings of pain, which might be the reason people suffering from CIP also don't feel pain. Wood thought that if he gave mice a medicine that reversed the effect of the opioid peptides, it may reverse the disorder. He gave the mice naloxone—a medication used to reverse opioid overdoses—and it worked. Wood figured the same could be done for humans. “After a decade of rather disap- pointing drug trials, we now have confirmation that Nav1.7 is a key element in human pain,” Woods says. “The secret ingredient turned out to be good old-fashioned opioid peptides, and we have now filed a patent for combining low dose opioids with Nav1.7 blockers. This should replicate the pain- lessness experienced by people with rare mutations, and we have already successfully tested this approach in unmodified mice.” CONGENITAL INSEN- SITIVITY TO PAIN (CIP) is a very rare genetic mu- tation that prevents mes- sages of physical pain from reaching the brain.

Research researcher and his team of researchers studied a 39-year-old woman with CIP. Using a laser beam and a dose of naloxone, Wood helped the woman, who elected to partici- pate anonymously, feel pain for the first time in her life. “Used in combination with Nav1.7 blockers, the dose of opioid needed to prevent pain is very low,” says Wood in an UCL release. “People

Using a test subject with a ge- netic mutation that prevents her from feeling pain, scientists have conducted research that shows promise in creating more effec- tive painkillers—and potentially decreasing the need for addictive opioids. Congenital insensitivity to pain (CIP) is a very rare genetic muta- tion that prevents messages of physical pain from reaching the brain. Sufferers of the disorder, as babies, will chew their lips until they bleed. Toddlers have to deal with more potential for falls, bumps and being hurt by hot or sharp things. Adults are at a high- er risk of dying prematurely. The disorder leaves those afflict- ed without channels known as Nav1.7, which carry sodium to sensory nerves. Understanding this disorder and channels of pain reception and delivery has led re- searchers to study the disorder for ways to block pain in those who don't have the disorder. Research- ers thought they could block pain transporting channels in people without CIP so they can help those with chronic and painful ailments like arthritis. HELPING A WOMAN CRY In a study published by the journal Nature, John Wood, a University College London (UCL) Wolfson Institute for Biomedical

with nonfunctioning Nav1.7 produce low levels of opioids throughout their lives without de- veloping tolerance or experiencing unpleasant side effects.”

As for this work leading to com- plete cessation of pain, Wood tells the New Scientist that some research has found success, but nothing has led to the complete pain loss found in those that are naturally without Nav1.7 channels.

who doesn’t feel the Woman WHAT THE FUTURE HOLDS.... As for people with CIP, Woods says he doesn't know if treatment using nalox- one is an option. Long-term use of naloxone could have side effects. What Woods can say, definitively, is that the mice in the experiment felt as little pain as mice who did not have the Nav1.7 channel naturally. Woods, his team, and the rest of the field are working to fill in the re- search gaps to start answering these questions for humans. “We hope to see our approach tested in human trials by 2017 and

Could help in making better painkillers.

we can then start looking into drug combinations to help the millions of chronic pain patients around the world,” Woods says. Imperial College London professor Kenji Okuse reacted to Wood’s findings to the New Scientist, saying that the research will provide more information to doc- tors about pain.

We hope to see our

“Opioids and Nav1.7 blockers could provide much stronger analgesics, but they will not necessarily be better for patients,” Okuse says. “If we take the combination therapy route, people would have to take opioids throughout the lifetime, which is not a welcome thing.”

approach tested in human trials by 2017 and we can then start looking

into drug combinations to help the millions of chronic pain patients around the world. — John Wood, University College London Wolfson Institute for Biomedical Research researcher

Lutheran Social Services of Illinois CONTACT US TODAY! 847.635.4600 issi.org

675 Varsity Dr. Elgin, IL 60120

0 END THE

"Not only are the recommendations comprehensive they were developed with input from a wide range of stake- holders, and wherever possible draw from evidence-based research:'

SENSEOF URGENCY

“This is a complex epidemic with no simple solutions.” —Dr. G. Caleb Alexander, co-director of the Johns Hop- kins Center for Drug Safety and

847.635.4600

675 Varsity Dr. Elgin, IL 60120

issi.org

INSERT 5

32

“It’s really just about being around like-minded people and developing that ‘we’ as a support system.”

– Dr. Gerard Love, Slippery Rock University

INSERT 5 “It’s really just about being around like-minded people and developing that ‘we’ as a support system,” Dr. Love says. Dr. Love says simply having a recovery space

“Universities are supposed to be about dialogue, and having this is a great opportunity for dialogue,” Dr. Love says. “Bringing this whole notion of addiction out of the shadows and increasing understanding, I think will be a good byproduct of this.”

on a college campus could help change perceptions about recovery and remove the stigma surrounding addiction.

Of cials at the University of Minnesota – Rochester will also be opening a new recovery LLC for the fall 2016 semester. Of cials say it’s necessary to provide recovering students with the tools they need to succeed academically and in their personal lives. “Historically, students who are in recovery really struggle to come back to campus without that [supportive housing] program,” says Kris Barry, the school’s health and wellness advocate. The LLC will house six to 10 students and feature evidence-based recovery programming. Of cials say the LLC speaks to the school’s mission as a health-focused university. But more than that, they say they hope to foster a culture of personal growth among all students, particularly those in recovery. “I see them as being leaders here on campus and then taking that and changing the dialogue about addiction,” Barry says. “We know that the traditional college experience can be hostile to the goals of anyone in recovery, and we want to support them as much as possible.”

Boyd Austin says student communities centered on recovery provide a welcome relief for students to explore their university in a supportive and positive way. “It o ers a space, it o ers a culture, it o ers a community of people who are engaging in college in the same way,” Boyd Austin says.

Experts say universities are increasingly adding recovery programs focused on creating a community among students, but ones incorporating housing are still few and far between. “This started about 30 years ago, but it has really taken off in the last 10 years,” says Amy Boyd Austin, president-elect of the Association of Recovery in Higher Education.

33

issi.org 847.635.4600

Lutheran Social Services of Illinois 847.635.4600 issi.org

675 Varsity Dr. Elgin, IL 60120

LSSI brings healing,justice and wholeness to people and communities

675 Varsity Dr. Elgin, IL 60120 • 847.741.2600 1001 E. Touhy Avenue, Des Plaines, IL 60018 • 847.635.4600 5825 W. Belmont Ave. Chicago, IL 60634 • 773.637.0487